Angiotensin-converting enzyme inhibitor (ACEI)/angiotensin II receptor blockers (ARBs), used as first-line hypertension therapies, have demonstrated antiinflammatory effects,15,16 specifically by blocking angiotensin-converting enzyme 2 (ACE2) downregulation-induced hyperactivation of the RAAS and attenuating oxidative stress, vasoconstriction, and inflammation.7 Here, ACE2 is linked to hypertensive disorder.